Compare AbbVie Inc (ABBV) vs Block Inc (XYZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Block Inc — how do they compare? AbbVie Inc trades at $247.47 (market cap $441.94B), while Block Inc trades at $77.78 (market cap $47.50B). The key difference: AbbVie Inc is far larger — about 9.3× Block Inc's market cap, and AbbVie Inc pays a 2.77% dividend while Block Inc pays none. Which is the better fit depends on your goals.
| ABBV | XYZ | |
|---|---|---|
Market Cap | $441.94B | $47.50B |
Sector | Health | Technology |
52-Week High | $263.58 | $84.64 |
52-Week Low | $197.38 | $49.04 |
Enterprise Value | $506.19B | $42.41B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.9, up 0.8% on the day, with strong analyst support (29 Buy, 1 Sell) and a $278.69 consensus price target. Recent quarterly earnings have consistently beaten estimates, driven by robust immunology drug sales. The stock shows a bullish technical trend, supported by moving averages, and the company maintains solid cash flow and dividend payments.
Outlook is positive with revenue growth and pipeline advancements, though high P/E and debt levels pose risks. The stock offers a compelling buy case for growth and income investors, balanced by execution and patent expiry challenges ahead.
XYZ trades at $77.78, down 1.52% on the day, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat expectations with EPS of $1.02 versus $0.871, driven by 25% gross profit growth in Cash App and Square. The company raised its 2026 profit outlook, reflecting operational momentum amid strategic AI integration and workforce optimization.
The outlook is positive given raised guidance and expanding profitability, but risks include high P/E valuation and net cash flow volatility. Analyst price targets average $99.47, suggesting 28% upside, supported by institutional accumulation and bullish earnings revisions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Block Inc
Founded in 2009, Block provides payment acquiring services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. Block has operations in Canada, Japan, Australia, and the United Kingdom
Read more on XYZ →
